Chemotherapy-induced Peripheral Neuropathy
Conditions
Keywords
brain stimulation, chemotherapy induced peripheral neuropathy
Brief summary
Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin)
Detailed description
Chemotherapy induced peripheral neuropathy (CIPN) occurs in conjunction with the use of anticancer medication such as vinca alkaloids (including vincristine), taxanes (including paclitaxel), and platinum preparations (including cisplatin and oxaliplatin) . CIPN is one of several long term side effects of anticancer medications that can appear during and after treatment. CIPN symptoms include pain, dysesthesia, motor and sensory disorders. CIPN can also be insufficiently responsive to pharmaceutical therapy similar to other types of refractory neuropathic pain This study is designed to evaluate the effect of two concentric electrode transcranial direct current stimulation (CE-tDCS) over the primary motor cortex (M) in management of chemotherapy induced peripheral neuropathy.
Interventions
DEVICEtranscranial dirrect current brain stimuation
tDCS (2 mA) targeting the primary motor cortex of the contralateral side of the painful side for 20 minute duration for five sessions in five consecutive days (one session /day),
Sponsors
Assiut University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Outcomes Assessor)
Eligibility
Sex/Gender
ALL
Age
18 Years to 70 Years
Healthy volunteers
No
Inclusion criteria
* any stage of cancer, with a confirmed treatment plan consisting of taxane-based or oxaliplatin-based chemotherapy, neuropathic pain and/or peripheral sensory neuropathy with VAS score ≥ 3 that are resistant to medical treatment
Exclusion criteria
* patients with intracranial metallic devices or with pacemakers or any other device. - -W those with extensive myocardial ischemia, * higher brain dysfunction, * migraine headache, * brain cancer or metastasis and * those known to have epilepsy
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| changes in the visual analogue scale | 0 (prestimulation), on the 5th day, 15th days and one month after the last session | patient describe his pain scored from 0 to 10 where 0=no pain and 10=the worst pain imaginable |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in the Leeds Assessment of neuropathic Symptoms and signs (LANSS) | 0 (prestimulation),on the 5th day, 15th days and one month after the last session | the patients will be asked to describe his pain by answering questions in yes or no; score ≥ 12 suggests neuropathic pain is likely to be involved and score \< 12 suggests that neuropathic pain is unlikely to be involved |
Countries
Egypt
Contacts
Primary ContactShereen M Kamal, Associate professor
Outcome results
None listed